Literature DB >> 11032331

Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.

V Leuzzi1, M C Bianchi, M Tosetti, C L Carducci, C A Carducci, I Antonozzi.   

Abstract

Recent studies using in vivo proton magnetic resonance spectroscopy (1H MRS) have suggested that plasma phenylalanine (Phe) may not be a reliable indicator of brain Phe level in subjects with phenylketonuria (PKU). Interindividual variation in cerebral Phe can contribute to the phenotypic variability of the disease. We report the results of the direct assessment of brain Phe by 1H MRS in 10 off-diet PKU patients (aged 15.5-30.5 years), 4 detected and treated early, 6 late. In a single patient, brain Phe was evaluated before and 15 days after diet discontinuation. FLAIR MRI and 1H MRS were performed in the same setting by a 1.5 T clinical MR scanner. MR images were scored according to the extent of the lobar white-matter hyperintensity. Brain 1H MRS Phe signal (resonating at 7.36 ppm) was evaluated as a ratio to the creatine+phosphocreatine signal. Brain Phe was correlated with clinical, biochemical and MRI findings. Results were as follows. (1) An abnormal concentration of brain Phe was detected in all 10 PKU subjects (ranging from 0.030 to 0.074), associated with a wide interindividual variability of concurrent plasma Phe (ranging from 724 to 2800 micromol/L). (2) In late-detected subjects, brain Phe concentration correlated with clinical phenotype better than did plasma Phe. The discrepancy between brain and plasma Phe was relevant from a clinical point of view in two cases: in one, a late-detected patient with normal mental development, a high level of plasma Phe was associated with a relatively low concentration of brain Phe; in the other, a late-detected subject with severe neurological impairment, a very high level of brain Phe was associated with plasma Phe compatible with the diagnosis of mild PKU. (3) White-matter alterations were detected in all patients. FLAIR MRI sequences disclosed an involvement of optic chiasma and tracts in 7 subjects. No correlation was found between white-matter alterations and concurrent brain Phe concentrations. (4) In the only case assessed under different intake of Phe, the relevant increase of brain Phe paralleled the concurrent increase of plasma Phe, showing that 1H MRS can be a useful tool in evaluating the individual vulnerability of PKU patients to different values of plasma Phe.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032331     DOI: 10.1023/a:1005621727560

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1.

Authors:  M Mascalchi; M Tosetti; R Plasmati; M C Bianchi; C Tessa; F Salvi; M Frontali; F Valzania; C Bartolozzi; C A Tassinari
Journal:  Ann Neurol       Date:  1998-02       Impact factor: 10.422

2.  Atypical phenylketonuria with borderline or normal intelligence.

Authors:  D Y Hsia; M E O'Flynn; J L Berman
Journal:  Am J Dis Child       Date:  1968-08

3.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment.

Authors:  J Pietz; R Kreis; H Schmidt; U K Meyding-Lamadé; A Rupp; C Boesch
Journal:  Radiology       Date:  1996-11       Impact factor: 11.105

5.  Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria.

Authors:  G M Knudsen; S Hasselbalch; P B Toft; E Christensen; O B Paulson; H Lou
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols.

Authors:  R Kreis; N Farrow; B D Ross
Journal:  NMR Biomed       Date:  1991-04       Impact factor: 4.044

7.  Brain MRI changes in phenylketonuria. Associations with dietary status.

Authors:  A J Thompson; S Tillotson; I Smith; B Kendall; S G Moore; D P Brenton
Journal:  Brain       Date:  1993-08       Impact factor: 13.501

Review 8.  Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.

Authors:  F Güttler
Journal:  Acta Paediatr Scand Suppl       Date:  1980

9.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

10.  Neuroradiological (MRI) abnormalities in phenylketonuric subjects: clinical and biochemical correlations.

Authors:  V Leuzzi; G F Gualdi; F Fabbrizi; G Trasimeni; C Di Biasi; I Antonozzi
Journal:  Neuropediatrics       Date:  1993-12       Impact factor: 1.947

View more
  11 in total

Review 1.  Key concepts in MR spectroscopy and practical approaches to gaining biochemical information in children.

Authors:  Loukas G Astrakas; Maria I Argyropoulou
Journal:  Pediatr Radiol       Date:  2016-05-27

2.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

3.  Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion.

Authors:  T Scarabino; T Popolizio; M Tosetti; D Montanaro; G M Giannatempo; R Terlizzi; S Pollice; A Maiorana; N Maggialetti; A Carriero; V Leuzzi; U Salvolini
Journal:  Radiol Med       Date:  2009-03-10       Impact factor: 3.469

4.  Prevalence of classical phenylketonuria in mentally retarded individuals in Iran.

Authors:  N M Ghiasvand; A Aledavood; R Ghiasvand; F Seyedin Borojeny; A R Aledavood; S Seyed; W Miner; G R Saeb Taheri
Journal:  J Inherit Metab Dis       Date:  2009-09-19       Impact factor: 4.982

5.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

6.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

Review 7.  MR spectroscopy in pediatric neuroradiology.

Authors:  Roberto Liserre; Lorenzo Pinelli; Roberto Gasparotti
Journal:  Transl Pediatr       Date:  2021-04

8.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

Review 9.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

10.  Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.

Authors:  Roman Trepp; Raphaela Muri; Stephanie Abgottspon; Lenka Bosanska; Michel Hochuli; Johannes Slotboom; Christian Rummel; Roland Kreis; Regula Everts
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.